Abstract
Background Two decades of genome-wide association studies (GWAS) have led to the fast-growing application of polygenic risk prediction (PRS). However, due to population structure and evolutionary path differences, the PRS substrate derived mostly from studies of European ancestry does not work equally well for other ancestries. There is an association between prediction accuracy decay and individual genetic distance (GD) to the genetic centers (GC) of various populations.
Objectives
To develop a new PRS method and software that utilizes individual GD to improve PRS risk prediction accuracy, especially for non-European populations.
Method
We hypothesize that adding a GD-based weight into PRS methods would enhance its risk prediction performance, particularly for minority groups. We explore the GD first by principal components (PC) and then by phylogenetic tree structures. Building on top of an emerging software (PRS-CSx) that achieves high prediction accuracy across multiple-ancestries, we present PGS-GRID, where “GRID” stands for “Genetic Reference based on Individual Distance”.
Results
We developed a preliminary version of PRS-GRID and pilot tested its prediction performance for a classic quantitative trait (e.g., height) and a disease trait (e.g., type-2 diabetes). We found slight but noticeable improvement of risk prediction in minority populations. We further explored a random forest approach so that the performance of PRS-GRID could be clearly explained, which is a key step for PRS to be used in clinical and public health practice.
Conclusions
The PRS-GRID philosophy and method represent an innovative and significant advancement in the field of polygenic risk prediction. Our work provides a foundation for future research and clinical applications aimed at reducing health disparities and improving population health through personalized medicine.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Figure 1 is revised, to be more clear.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.